Skip to content

Press Releases

You will find all our regulatory press releases in the feed below. Enjoy and share all our other Asarina Pharma news in our regularly updated News Archive.

Asarina Pharma: Issuance of 700,000 warrants completed

Stockholm, 28 May 2021: Asarina Pharma AB (publ) today announces that it has issued 700,000 new warrants which have all been acquired by the management and other members of the Asarina staff.

Full PDF

Asarina Pharma receives approval of CTA for phase IIa Tourette study

(Stockholm, 19 May, 2021.) Asarina Pharma’s Clinical Trial Application for a phase IIa study with Sepranolone in Tourette Syndrome has been approved by the Danish Medical Agency, with the study to commence in August 2021 at two sites in Denmark.

Full PDF

Asarina Pharma AB (publ) Q1 Report 2021 released

Asarina Pharma CEO Peter Nordkild: “The first quarter 2021 has been busy and exciting. We are moving decisively towards completing our Menstrual Migraine phase IIa study with the last patient’s last visit on April 8. We are on schedule to publish topline results for the study before the end of June. In Tourette Syndrome we…

Full PDF

Bulletin from the Annual General Meeting of Asarina Pharma AB (publ)

The following resolutions were passed at the annual general meeting (the “AGM”) of Asarina Pharma AB (publ) (“Asarina Pharma”) on 21 April 2021 in Stockholm. The CEO’s presentation is available at the company’s website.

Full PDF

NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (PUBL)

The shareholders of Asarina Pharma AB (publ), reg. no. 556698-0750, (the “Company”) are hereby summoned to attend the Annual General Meeting (the “AGM”) on 21 April 2021 at 10.00 CEST at Erik Penser Bank, Apelbergsgatan 27 in Stockholm. Registration starts at 09.30 CEST.

Full PDF